AZ’s COVID-19 vaccine trial ready to resume in US – reportsAstraZeneca’s COVID-19 vaccine trial could be ready to resume this week in the US after a seven-week hiatus Share XAZ’s COVID-19 vaccine trial ready to resume in US – reportshttps://pharmaphorum.com/news/azs-covid-19-vaccine-trial-ready-to-resume-reports/
Trump launches tirade against NIAID chief Fauci as COVID-19 crisis escalatesThe war of words between Donald Trump and his top infectious diseases expert Dr Anthony Fauci has intensified Share XTrump launches tirade against NIAID chief Fauci as COVID-19 crisis escalateshttps://pharmaphorum.com/news/trump-launches-tirade-against-niaid-chief-fauci-as-covid-19-crisis-escalates/
UK government signs contract for COVID-19 challenge trialThe UK government has signed a contract to develop a controversial COVID-19 human challenge trial, where participants will Share XUK government signs contract for COVID-19 challenge trialhttps://pharmaphorum.com/news/uk-government-signs-contract-for-covid-19-challenge-trial/
Rare diseases, repurposing and the role of AIIn the age of artificial intelligence, no trial data should be going to waste. Findacure’s Rick Thompson looks Share XRare diseases, repurposing and the role of AIhttps://pharmaphorum.com/r-d/views-analysis-r-d/rare-diseases-repurposing-and-the-role-of-ai/
Innovation boosts R&D outlook despite COVID difficulties – reportAyming Group’s second annual International Innovation Barometer (IIB) has said that the international outlook for R&D is “remarkably Share XInnovation boosts R&D outlook despite COVID difficulties – reporthttps://pharmaphorum.com/r-d/views-analysis-r-d/innovation-boosts-rd-outlook-despite-covid-difficulties-report/
Flying the flag for research in Aarskog syndromeDelayed diagnosis, lack of awareness, and a limited evidence base – Aarskog syndrome faces all the challenges of Share XFlying the flag for research in Aarskog syndromehttps://pharmaphorum.com/views-analysis-patients/flying-the-flag-for-research-in-aarskog-syndrome/
Introducing the new NIHR National Patient Recruitment CentresThe five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical Share XIntroducing the new NIHR National Patient Recruitment Centreshttps://pharmaphorum.com/webinars/nihr-national-patient-recruitment-centres/
Vaccines trials in the COVID-19 era and tech’s role in speeding studiesOverview The COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus Share XVaccines trials in the COVID-19 era and tech’s role in speeding studieshttps://pharmaphorum.com/r-d/vaccines-trials-covid-19-coronavirus/
The COVID-19 coronavirus and pharma and biotech continuity planningOverview Pharmaceutical and biotech companies around the globe are working with Governments to address the COVID-19 outbreak, from Share XThe COVID-19 coronavirus and pharma and biotech continuity planninghttps://pharmaphorum.com/r-d/the-potential-impact-of-coronavirus-covid-19-for-global-pharma-and-biotech-continuity/
J+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTERFC+, Pharma Forecasting Software has been upgraded Share XJ+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTERhttps://pharmaphorum.com/partner-content/jd-forecasting-makes-the-pharma-forecasting-experience-even-better/
PPE for Infection Control Market Will Touch $17.1 Billion By 2026Global Market Insights, Inc., report forecasts the personal protective equipment for infection control industry to grow at a Share XPPE for Infection Control Market Will Touch $17.1 Billion By 2026https://pharmaphorum.com/partner-content/ppe-for-infection-control-market-will-touch-17-1-billion-by-2026/
Dermatology Devices Market Size Will Achieve 11.9% CAGR From 2019 To 2025The global dermatology devices market size is expected to reach USD 20 billion by 2025, at a CAGR of Share XDermatology Devices Market Size Will Achieve 11.9% CAGR From 2019 To 2025https://pharmaphorum.com/partner-content/dermatology-devices-market-size-will-achieve-11-9-cagr-from-2019-to-2025/
